Shares of U.S.-listed companies connected to Greenland, including Greenland Energy, Greenland Mines, and Critical Metals Corp, surged significantly following a new security agreement between the U.S., Denmark, and Greenland. The pact aims to expand the U.S. military presence in Greenland to prevent adversaries from establishing bases in the Arctic territory. This deal, expected to be signed at the upcoming United Nations General Assembly, highlights Greenland's strategic importance amid previous U.S. interest in the region. The development could impact geopolitical dynamics and investment interest in Arctic resources.
The U.S.-listed Greenland stocks and related companies are the subject, with Pluang's Basic Materials sector data providing market context. As of Sep 21, 2026 15:41 WIB, 20 of 34 priced Basic Materials-sector US stocks on Pluang rose while 10 fell. Notable prices include ArcelorMittal SA at USD 73.22 with a 0.94% increase, Rio Tinto (ADR) at USD 98.27 up 0.92%, and Vale SA at USD 14.33 rising 0.84%.
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Shurgard Self Storage, a leading European self-storage REIT, is currently trading at a significant discount to its net tangible assets (NTA) with a valuation of 0.48x NTA. It offers an attractive dividend yield of 4.5% and benefits from strong urbani...
Kiniksa Pharmaceuticals International, plc announced that its management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 16, 2026. The event will be webcast live and available for replay on the ...
Lakefront Biotherapeutics reported a net profit of €13.9 million for the first nine months of 2026, a significant turnaround from a €461.3 million loss in the same period last year. The company highlighted progress with its autoimmune drug gamgertami...
